Course Director
Vincenzo Valentini, Radiation Oncologist, Università Cattolica S.Cuore, Rome (IT)
Course Local Co-Director
Zoran Krivokapic, Surgeon, First Surgical Clinic, Clinical Center of Serbia, Belgrade (RS)
Teachers
Regina Beets-Tan, Radiologist, University Hospital Maastricht, Maastricht (NL)
Josep M Borras, Epidemiologist, Cancer Plan, Dept. of Health. L'Hospitalet de Llobregat. Barcelona (ES)
Claudio Coco, Surgeon, Università Cattolica S.Cuore, Rome (IT)
Karin Haustermans, Radiotherapist, University Hospital Gasthuisberg, KU-Leuven (BE)
Corrie Marijnen, Radiation Oncologist, Nederlands Kanker Instituut, Amsterdam (NL)
Lars Påhlman, Surgeon, Uppsala University Hospital, Uppsala (SE)
Claus Rödel, Radiation Oncologist, University Hospital Erlangen, Erlangen (DE)
Hans Joachim Schmoll, Medical Oncologist, Martin Luther University Halle-Wittenberg, Halle (DE)
Nigel Scott, Pathologist, St James¹s University Hospital, Leeds (UK)
Cornelius Van de Velde, Surgeon, Leiden University Medical Center, Leiden (NL)
Local Organising Committee
Nenad Borojevic, Velimir Markovic, Goran Barisic, Jelena Petrovic, Milos Popovic, Ivan Dimitrijevic
Course aim
This course, jointly organized by ESTRO, ESSO and ESMO wants to promote an integrated approach between all specialists involved in rectal cancer to tailor the best treatment for each individual patient. The treatment of rectal carcinoma is as variable as its clinical presentations. During the past decades surgical approaches have become more standardized with the introduction of total mesorectal excision and new surgical technologies allowing endoscopic surgical procedures and local excision by transanal endoscopy microsurgery are now available in many centres. A broad spectrum of treatment modalities have been examined such as preoperative radiotherapy short course (5 Gy in 5 days), long course (alone or in combination with 5FU based regimens or with new drugs), IORT in primary disease, postoperative radiochemotherapy with different 5FU based schedules, and combinations of drugs in patients with metastatic disease. New imaging techniques are now allowing a better definition of tumour extension and staging. With a combination of lectures, case discussions in small groups and debates, the course aims to offer a truly multidisciplinary programme, focusing on the advantages of the different treatments for the different presentations of rectal cancer (evidence) and ongoing and future research in rectal cancer.
Target Group
The target group consists of surgeons, radiotherapists and medical oncologists involved in the multidisciplinary treatment of rectal cancer.
Educational programme
Thursday, 20 May 2010
• Differences in rectal cancer treatment across Europe and Asia
• Evidence based platform : Radiology; Pathology; Surgery;Radiotherapy; chemotherapy
• Small Work Group: Early stage
• MDT (Multidisciplanry Team) Early Stage: Pathology, Radiology, Surgery, Radiotherapy
• General Debate: Early stage
• Standard Technical Platform : Molecular Pathology; Surgery; Local excision; Surgery TME; Surgery Exenteration; Radiology; Radiotherapy 2D/3D; Radiotherapy IMRT/D; Radiotherapy Toxicity
Friday, 21 May 2010
• Small Work Group: Intermediate CRM - Stage
• MDT Intermediate CRM Stage : Pathology; Radiology; Surgery; Radiotherapy pre vs post; 5x5 and CRT
• General Debate: Intermediate CRM - Stage
• Small Work Group: Intermediate CRM+/cT4 Stage
• MDT Intermediate CRM+/cT4 Stage: Pathology; Radiology; Surgery; Radiotherapy 5x5; Radiotherapy CRT; Chemotherapy
Saturday, 22 May 2010
• General Debate: Intermediate CRM+/cT4 Stage
• Small Work Group: Advanced Metastastic stage
• MDT Adanced Metastatic Stage: Radiology; Pathology; Surgery; Radiotherapy; Chemotherapy
• General Debate: Advanced Metastatic stage
• Follow-up
• How the research will help us to tailor the treatment in: Surgery; Radiotherapy; Medical Oncology
• Take Home Messages